Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single Ascending Doses of REGN5381 in Heart Failure Patients With Elevated Pulmonary Capillary Wedge Pressure
2021-006337-19Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) comparing REGN5381 single ascending dose with Placebo (2 arms). Primary endpoint: Incidence and severity of treatment-emergent adverse events. Started Mar 2022; status: completed.
02
Drugs
REGN5381
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2021-006337-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006337-19.